Genmab experienced strong upward momentum following significant clinical pipeline breakthroughs and bullish sell-side adjustments. The primary catalyst behind the buying surge was the presentation of encouraging Phase 1/2 RAINFOL-01 trial data for rinatabart sesutecan, an antibody-drug conjugate targeting platinum-resistant ovarian cancer, at the International Gynecologic Cancer Society Congress. The trial demonstrated compelling response rates and durable progression-free survival across diverse patient populations. Additionally, positive top-line Phase 3 results from the EPCORE DLBCL-2 trial evaluating epcoritamab in combination with standard care for diffuse large B-cell lymphoma further reinforced confidence in the company’s…